About Eiger Biopharmaceuticals (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138
Debt
Debt-to-Equity Ratio0.58%
Current Ratio5.85%
Quick Ratio5.85%
Price-To-Earnings
Trailing P/E Ratio-1.98
Forward P/E Ratio-2.21
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book4.36
Profitability
EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-196.04%
Return on Assets-101.44%
Miscellaneous
Employees16
Outstanding Shares10,530,000
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) issued its earnings results on Monday, March, 12th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.02) by $0.09. View Eiger Biopharmaceuticals' Earnings History.
When is Eiger Biopharmaceuticals' next earnings date?
What price target have analysts set for EIGR?
7 brokers have issued 1 year price targets for Eiger Biopharmaceuticals' stock. Their forecasts range from $17.00 to $35.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $29.00 in the next twelve months. View Analyst Ratings for Eiger Biopharmaceuticals.
What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (3/22/2018)
- 2. Wedbush analysts commented, "The Wedbush View: With four drug candidates being tested in four indications and enough cash runway to cover data readouts over the next 12 months, we believe EIGR is trading at an attractive value and recommend shares to investors." (6/21/2017)
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Vericel (VCEL), Nightstar Therapeutics (NITE), Agenus (AGEN), Cellular Biomedicine Gr (CBMG), Idera Pharmaceuticals (IDRA), Adverum Biotechnologies (ADVM), NantKwest (NK), Allena Pharmaceuticals (ALNA), Osiris Therapeutics (OSIR), Fennec Pharmaceuticals (FENC), NanoString Technologies (NSTG), Arsanis (ASNS), ADMA Biologics (ADMA), Compugen (CGEN) and Pluristem Therapeutics (PSTI).
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Pres, CEO, Director & Bus. Founder (Age 54)
- Dr. Jeffrey S. Glenn M.D., Ph.D., Founder, Scientific Advisor & Director (Age 55)
- Dr. Joanne M. J. Quan M.D., Chief Medical Officer (Age 54)
- Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 51)
- Mr. James A. Welch MBA, Chief Financial Officer (Age 60)
Has Eiger Biopharmaceuticals been receiving favorable news coverage?
News coverage about EIGR stock has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 0.03 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.08 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $9.32.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $110 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVENUE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eiger Biopharmaceuticals (NASDAQ:EIGR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Eiger Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 211.16%. The high price target for EIGR is $35.00 and the low price target for EIGR is $17.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $29.00 | $29.00 | $29.00 | $33.00 |
| Price Target Upside: | 211.16% upside | 205.26% upside | 81.25% upside | 194.64% upside |
Eiger Biopharmaceuticals (NASDAQ:EIGR) Consensus Price Target History
Eiger Biopharmaceuticals (NASDAQ:EIGR) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Eiger Biopharmaceuticals (NASDAQ:EIGR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.80%
Institutional Ownership Percentage: 69.22%
Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Joanne Quan | Insider | Sell | 4,000 | $10.00 | $40,000.00 | 4,000 |  |
| 9/1/2017 | Jeffrey S Glenn | Director | Buy | 15,000 | $9.53 | $142,950.00 | 31,355 | |
| 11/18/2016 | Jeffrey S Glenn | Director | Buy | 15,460 | $12.74 | $196,960.40 | 16,355 | |
| 8/18/2016 | James P Shaffer | Insider | Buy | 3,125 | $15.70 | $49,062.50 | 5,620 | |
| 8/18/2016 | Ventures Fund Vi L.P. Vivo | Major Shareholder | Buy | 187,500 | $16.00 | $3,000,000.00 | | |
| 6/22/2016 | James H Welch | CFO | Buy | 2,500 | $19.80 | $49,500.00 | 2,000 | |
| 6/13/2016 | James P Shaffer | Insider | Buy | 1,250 | $22.17 | $27,712.50 | 1,975 | |
| 5/23/2016 | James P Shaffer | Insider | Buy | 1,245 | $19.80 | $24,651.00 | 500 | |
| 4/6/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $18.20 | $872,344.20 | | |
| 4/2/2015 | Rebecque J Laba | VP | Sell | 11,012 | $17.30 | $190,507.60 | | |
| 3/9/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $24.80 | $1,188,688.80 | | |
| 3/6/2015 | Peter Honig | Director | Sell | 9,700 | $23.74 | $230,278.00 | | |
| 3/6/2015 | Rebecque J Laba | VP | Sell | 14,000 | $23.06 | $322,840.00 | | |
| 3/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $18.48 | $143,718.96 | | |
| 2/9/2015 | Krisztina M Zsebo | CEO | Sell | 47,931 | $15.86 | $760,185.66 | | |
| 2/6/2015 | Rebecque J Laba | VP | Sell | 14,000 | $16.08 | $225,120.00 | | |
| 2/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $16.35 | $127,153.95 | | |
| 1/9/2015 | Jeffrey J Rudy | VP | Sell | 10,000 | $18.51 | $185,100.00 | | |
| 1/7/2015 | Rebecque J Laba | VP | Sell | 20,000 | $17.30 | $346,000.00 | | |
| 1/6/2015 | Krisztina M Zsebo | CEO | Sell | 41,302 | $17.51 | $723,198.02 | | |
| 1/2/2015 | Ryan K Takeya | VP | Sell | 7,777 | $19.88 | $154,606.76 | | |
| 12/9/2014 | Jeffrey J Rudy | VP | Sell | 10,000 | $15.00 | $150,000.00 | | |
| 12/9/2014 | Krisztina M Zsebo | CEO | Sell | 41,302 | $15.00 | $619,530.00 | | |
| 12/5/2014 | Rebecque J Laba | VP | Sell | 20,000 | $12.77 | $255,400.00 | | |
| 12/1/2014 | Ryan K Takeya | VP | Sell | 7,777 | $12.01 | $93,401.77 | | |
| 2/4/2014 | Enterprise Partners Management | Major Shareholder | Buy | 133,083 | $8.00 | $1,064,664.00 | | |
| 2/4/2014 | Fredrik Wiklund | VP | Buy | 20,000 | $8.00 | $160,000.00 | | |
| 2/4/2014 | Todd Foley | Director | Buy | 111,608 | $8.00 | $892,864.00 | | |
(Data available from 1/1/2013 forward)
Eiger Biopharmaceuticals (NASDAQ EIGR) News Headlines
| Source: |
|
Eiger Biopharmaceuticals (NASDAQ:EIGR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eiger Biopharmaceuticals (NASDAQ:EIGR) Income Statement, Balance Sheet and Cash Flow Statement
Eiger Biopharmaceuticals (NASDAQ EIGR) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
